Emergent BioSolutions (EBS) Q3 2024 earnings summary

Executive summary

• Achieved critical stabilization milestones and entered the turnaround phase ahead of schedule, focusing on profitable growth and operational efficiency.

• Q3 2024 revenues rose 9% year-over-year to $293.8M, with net income of $114.8M, a significant turnaround from a net loss of $263.4M in Q3 2023.

• Raised 2024 revenue and adjusted EBITDA guidance, reflecting strong year-to-date results, new contract awards, and improved margins.

• Completed $117M in asset sales, including RSDL® and Baltimore-Camden facility, and resolved legacy legal matters with a $50M Janssen settlement.

• Strengthened leadership team with new executive appointments and streamlined operations to focus on core business drivers.

Financial highlights

• Q3 2024 total revenues reached $293.8M, up 9% year-over-year; YTD revenues were $848.9M, up 10% versus prior year.

• Q3 2024 adjusted EBITDA was $105.3M (36% margin), up 432% year-over-year; YTD adjusted EBITDA was $162.1M, up from $(25.7)M YTD 2023.

• Q3 2024 net income was $114.8M, compared to a net loss of $(263.4)M in Q3 2023; Q3 EPS was $2.06 diluted.

• Operating cash flow for the first nine months was $138.6M, a $377M improvement year-over-year.

• Net debt reduced by $206M since start of 2024, now at $551M; total liquidity at Q3 end was $250M, including $100M undrawn revolver.

Outlook and guidance

• 2024 full-year revenue guidance raised to $1.065–1.125 billion; adjusted EBITDA guidance increased to $180–200M.

• Adjusted net loss for 2024 expected at $(50)M to $(30)M; total segment adjusted gross margin projected at 43–45%.

• Commercial product sales expected at $420–430M; MCM product sales at $510–550M; services segment revenue forecasted at $105–110M.

• Management believes liquidity is sufficient to fund operations for at least the next twelve months.

• Quarterly results may vary due to timing of government contracts and product deliveries.